FreeStyle Libre

DexCom, Inc. (NASDAQ: DXCM) shares got hammered Sept. 28 when rival Abbott Laboratories (NYSE: ABT) received FDA approval for its FreeStyle Libre flash glucose monitoring system. Investors see Abbott’s new system as a lower-priced alternative to DexCom’s continuous glucose...

Despite a more than 35 percent plunge in DexCom, Inc. (NASDAQ: DXCM)'s stock, analysts at Canaccord Genuity continue to hold a bullish outlook. The firm's Kyle Rose maintains a Buy on DexCom's stock with a price target lowered from $90 to $69. DexCom's stock was hard hit on Thursday...